查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018481

獸醫腫瘤市場：依動物種類、治療方法、癌症類型、給藥途徑及最終用戶分類－2026-2032年全球市場預測

Veterinary Oncology Market by Animal Type, Treatment Mode, Cancer Type, Mode of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸醫腫瘤市場價值將達到 18.4 億美元，到 2026 年將成長到 20.9 億美元，到 2032 年將達到 47.4 億美元，複合年成長率為 14.47%。

主要市場統計數據
基準年 2025 18.4億美元
預計年份：2026年 20.9億美元
預測年份 2032 47.4億美元
複合年成長率 (%) 14.47%

全面概述正在改變獸醫腫瘤學並塑造未來策略決策的突破性創新和市場動態。

獸醫腫瘤學領域正步入一個關鍵時期，其特點是技術快速發展、臨床模式不斷演變，以及人們日益認知到癌症是伴侶動物發病率的主要促進因素。過去十年，分子診斷、微創治療和標靶治療取得了突破性進展，這些進展共同改善了患者的治療效果，並提升了獸醫的診療能力。隨著寵物飼主越來越希望獲得類似於人類腫瘤治療方案的複雜治療計劃，該行業面臨著對整合式診療路徑和精準醫療前所未有的需求。

透過技術進步、個人化醫療和合作研究模式，對變革進行深刻探索，這將徹底改變獸醫腫瘤學。

尖端診斷技術、精準醫療和協作研究框架的整合正在改變獸醫腫瘤學領域。近年來，基因測序的進步使獸醫能夠識別腫瘤特異性生物標記物，從而指南個人化治療方案的發展。此外，包括單株抗體和癌症疫苗在內的免疫調節劑的出現，也拓展了傳統化療方案以外的治療選擇。

評估美國關稅在 2025 年對獸醫腫瘤學供應鏈、研究成本和臨床實踐機會的廣泛和累積影響。

美國將於2025年實施的新關稅給整個獸醫腫瘤供應鏈帶來了巨大的成本壓力。對藥品化合物、診斷試劑和專用醫療設備的進口關稅增加了國內生產商和臨床服務提供者的採購成本。因此，生產利潤空間縮小，定價策略需要調整以消化關稅帶來的額外支出。對於依賴海外進口活性成分的治療方法而言，這一趨勢尤其嚴峻，因為外匯波動和關稅對整體成本結構的影響巨大。

從動物種類、治療方法方法、癌症類型、給藥途徑和最終用戶等方面進行關鍵細分洞察：影響市場複雜性的因素

要全面了解獸醫腫瘤學的複雜整體情況，需要深入研究影響市場動態的多面向細分領域。從動物種類來看，犬類癌症治療佔據了服務需求的大部分，這主要歸因於淋巴瘤和乳腺癌的高發病率；而貓科腫瘤學則因肥大細胞瘤的特殊治療方案而日益受到關注。馬科腫瘤學雖然仍是一個小眾但成長迅速的領域，尤其是在肉瘤和黑色素瘤方面。同時，涵蓋水生動物、鳥類、爬蟲類和兩棲動物的異寵領域，在標靶診斷和針對特定棲息地的治療方法展現出新的機會。

本研究分析了美洲、歐洲、中東和非洲以及亞太地區的關鍵區域見解，以揭示獸醫腫瘤學趨勢的地理差異。

區域趨勢對於理解獸醫腫瘤學如何塑造不同市場至關重要。在美洲，完善的獸醫基礎設施、較高的寵物擁有率和成熟的保險體系促進了先進治療方法和診斷技術的早期應用。美國憑藉監管嚴格的生態系統佔據主導，該系統支持快速商業化；而在拉丁美洲市場，對腫瘤學領域能力建設的投資正透過慈善活動和與學術機構的合作逐步推進。

透過創新和夥伴關係，來自塑造獸醫腫瘤領域競爭格局的主要企業的策略見解。

眾多主要企業正在重塑獸醫腫瘤領域的競爭格局，其特點是策略聯盟和針對性研發投資。全球製藥巨頭正在推出專門從事腫瘤藥物研發的動物用藥品部門，而中型專業公司則透過自主研發的生技藥品和疫苗平台實現差異化競爭。影像設備和軟體製造商正與獸醫醫院合作，將人工智慧驅動的分析工具整合到臨床工作流程中。

為行業領導者提供實用建議，以應對市場複雜性、最佳化資源分配並抓住獸醫腫瘤學領域的新興機會。

行業領導者必須採取積極主動的方式，抓住獸醫腫瘤領域的新興機遇，並降低不斷變化的風險。優先投資免疫療法研究將有助於打造差異化的產品平臺，同時擴大數位化醫療解決方案，提高診斷準確性和客戶參與。此外，與學術機構建立夥伴關係，將加速轉化研究成果的獲取，並提昇在臨床同行中的信譽度。

本文概述了一種穩健的調查方法，該方法結合了初次訪談、二次資料分析和嚴格的檢驗，以確保獸醫腫瘤學研究結果的可靠性。

本分析基於嚴謹的調查方法，此方法綜合運用了來自一手和二手資料來源的洞見。一手資料收集包括對獸醫腫瘤學家、診斷實驗室主任和學術研究人員進行詳細訪談，以了解他們對臨床療效、營運挑戰和未滿足需求的第一手觀點。二手研究則廣泛查閱了同行評審期刊、臨床試驗註冊資訊、專利申請和監管文件，以闡明技術進步和核准的過程。

本報告整合了關鍵發現、策略意義和行業趨勢，以清楚定義獸醫腫瘤學的現狀和未來方向。

總而言之，在技術突破、不斷演進的治療模式和策略性產業合作的推動下，獸醫腫瘤學正處於持續成長和創新階段。關鍵的細分市場洞察揭示了不同動物物種和治療方法之間存在的細微差異化機遇，而區域分析則強調了個人化方法對於市場准入和擴張的重要性。 2025年的關稅結構調整既帶來了挑戰，也為近岸外包和供應鏈最佳化提供了獎勵，這要求企業具備敏捷的領導力和靈活的策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：獸醫腫瘤市場：依動物類型分類

  • 狗
  • 馬
  • 異寵
    • 水生寵物
    • 鳥類
    • 爬蟲類和兩棲類
  • 貓

第9章 依治療方法的獸醫腫瘤市場

  • 化療
    • 烷化劑
    • 抗代謝物
    • 細胞毒性藥物
    • 長春花生物鹼
  • 免疫療法
    • 癌症疫苗
    • 單株抗體
  • 放射線治療
    • 近距離放射治療
    • 遠端輻射
  • 外科手術
  • 分子標靶治療

第10章：以癌症類型分類的獸醫腫瘤市場

  • 血管肉瘤
  • 淋巴瘤
  • 乳癌
  • 肥大細胞瘤
  • 骨癌

第11章 依給藥途徑分類的獸醫腫瘤市場

  • 靜脈注射（IV）
  • 口服
  • 外用

第12章 獸醫腫瘤市場：依最終用戶分類

  • 學術機構
  • 獸醫醫院和診所

第13章 獸醫腫瘤市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 獸醫腫瘤市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 獸醫腫瘤市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國獸醫腫瘤市場

第17章：中國獸醫腫瘤市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AB Science SA
  • Anivive Lifesciences
  • Ardent Animal Health, LLC
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Covetrus, Inc.
  • Elanco Animal Health Incorporated
  • ELIAS Animal Health
  • Fidocure
  • IDEXX Laboratories, Inc.
  • Karyopharm Therapeutics Inc.
  • Leroy Biotech SAS
  • Merck KGaA,
  • Morphogenesis, Inc.
  • Nippon Zenyaku Kogyo Co., Ltd.
  • PetCure Oncology LLC
  • PharmAust Limited
  • Rhizen Pharmaceuticals AG
  • Torigen Pharmaceuticals Inc.
  • Varian Medical Systems, Inc.
  • Vetco Pharmaceuticals Inc.
  • VetDC, Inc.
  • Virbac SA
  • VolitionRx Limited
  • Zoetis Inc.
Product Code: MRR-A339DAEF9FFF

The Veterinary Oncology Market was valued at USD 1.84 billion in 2025 and is projected to grow to USD 2.09 billion in 2026, with a CAGR of 14.47%, reaching USD 4.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.84 billion
Estimated Year [2026] USD 2.09 billion
Forecast Year [2032] USD 4.74 billion
CAGR (%) 14.47%

Unveiling a Comprehensive Introduction to the Breakthrough Innovations and Market Dynamics Transforming Veterinary Oncology and Informing Future Strategic Decisions

The veterinary oncology sector has entered a pivotal era defined by rapid technological progress, evolving clinical paradigms, and an increasing recognition of cancer as a dominant driver of morbidity in companion animals. Over the past decade, breakthroughs in molecular diagnostics, minimally invasive interventions, and targeted therapies have coalesced to advance both patient outcomes and practitioner capabilities. As pet owners grow more willing to pursue complex treatment regimens reminiscent of human oncology protocols, the industry is confronted with unprecedented demands for integrated care pathways and precision-driven therapeutics.

Moreover, the market dynamic is shaped by a convergence of factors including an aging pet population, heightened investment in translational research, and strategic partnerships between veterinary specialists and academic institutions. Consequently, stakeholders across pharmaceutical development, diagnostics, and clinical service delivery must navigate an increasingly sophisticated landscape that prioritizes efficacy, safety, and cost-effectiveness. In addition, regulatory bodies are progressively harmonizing standards related to drug approval and clinical trial design, setting the stage for accelerated product launches.

This executive summary distills the essential developments influencing veterinary oncology, from new tariff regimes impacting supply chains to granular segmentation insights that uncover niche growth pockets. By synthesizing prevalence trends, therapeutic innovations, and competitive dynamics, the following analysis equips decision-makers with a holistic perspective on current challenges and future trajectories. Readers will gain a clear understanding of transformative shifts, regional variances, company strategies, and actionable recommendations tailored to safeguard and amplify market positioning.

Exploring the Profound Transformative Shifts Revolutionizing Veterinary Oncology Through Technological Advancements, Personalized Care, and Collaborative Research Models

The veterinary oncology landscape is undergoing transformative shifts driven by the integration of cutting-edge diagnostics, precision therapeutics, and collaborative research frameworks. In recent years, advancements in genomic sequencing have enabled practitioners to identify tumor-specific biomarkers that inform individualized treatment plans. Furthermore, the emergence of immunomodulatory agents, including monoclonal antibodies and cancer vaccines, has expanded therapeutic arsenals beyond traditional chemotherapeutic regimens.

Simultaneously, radiation therapy techniques are benefiting from enhanced dosimetric planning and imaging modalities, allowing for targeted tumor ablation with reduced collateral tissue damage. Telemedicine platforms and digital pathology applications are streamlining case reviews and interdisciplinary consultations, thus accelerating decision-making and fostering knowledge exchange among oncology specialists. In addition, artificial intelligence and machine learning algorithms are being piloted to predict treatment responses, monitor disease progression, and optimize dosing strategies, representing a fundamental shift towards data-driven clinical protocols.

Moreover, the proliferation of specialized oncology centers within veterinary hospitals and the deepening engagement of academic institutions in clinical research are reinforcing a robust innovation pipeline. Partnerships between industry and academia are facilitating the translation of preclinical findings into veterinary-approved products, while cross-border collaborations extend access to novel therapies. As a result, veterinary oncology is transitioning from a nascent discipline to a mature ecosystem where multidisciplinary synergy drives continuous improvement in patient care and commercial viability.

Assessing the Far-Reaching Cumulative Impact of United States Tariffs on Veterinary Oncology Supply Chains, Research Costs, and Clinical Accessibility in 2025

The implementation of new United States tariffs in 2025 has introduced material cost pressures across the veterinary oncology supply chain. Import duties on pharmaceutical compounds, laboratory reagents, and specialized medical equipment have elevated procurement expenses for both domestic manufacturers and clinical service providers. Consequently, production margins are contracting, and pricing strategies must be recalibrated to absorb incremental tariff-related outlays. This dynamic is particularly acute for therapies reliant on active pharmaceutical ingredients sourced internationally, where exchange rate fluctuations and customs duties compound overall cost structures.

Furthermore, research and development initiatives are being influenced by the recalibrated economics of cross-border collaboration. Academic and biotech partners are reassessing the viability of joint programs that require frequent reagent transfers or clinical trial material shipments. In response, organizations are exploring localized manufacturing capabilities and nearshoring strategies to mitigate tariff exposure and streamline logistics. Regulatory pathways are also being reviewsed to accommodate in-country production of critical oncology drugs, thereby reducing dependency on imported supply and enhancing resilience against future trade policy shifts.

In addition to supply chain ramifications, practitioners are confronting the downstream impact on treatment affordability and accessibility. Pet owners facing elevated out-of-pocket expenses may delay or forgo recommended protocols, which could affect clinical outcomes and long-term revenue streams for service providers. As such, stakeholder dialogues are intensifying around alternative financing models, insurance partnerships, and tiered therapy frameworks to ensure that high-value oncology care remains within reach for a broad demographic of companion animal caretakers.

Revealing Key Segmentation Insights Across Animal Types, Treatment Modalities, Cancer Categories, Administration Modes, and End Users Driving Market Complexity

Understanding the complex mosaic of veterinary oncology requires a deep dive into multiple dimensions of segmentation that collectively shape market dynamics. When examining animal type, canine cancer care dominates service demand, driven by a high incidence of lymphoma and mammary carcinoma, while feline oncology is gaining traction through specialized protocols for mast cell tumors. Equine oncology remains a niche yet growing category, particularly for sarcoids and melanomas, whereas the exotic pets segment-comprising aquatic species, avian populations, and reptile and amphibian communities-presents emergent opportunities for targeted diagnostics and habitat-specific treatment regimens.

Treatment mode segmentation reveals a diversified therapeutic toolkit. Chemotherapy, with its subdivisions of alkylating agents, antimetabolites, cytotoxic compounds, and Vinca alkaloids, continues to be a mainstay. At the same time, immunotherapy platforms leveraging cancer vaccines and monoclonal antibodies are redefining response paradigms. Radiotherapy innovations, spanning brachytherapy to external beam radiotherapy, offer precision interventions that complement surgical excision and the expanding field of targeted molecular therapies.

Additional segmentation by cancer type highlights distinct prevalence and research priorities, with hemangiosarcoma and osteosarcoma presenting acute diagnostic and therapeutic challenges. Mode of administration, whether intravenous infusion, oral dosing, or topical application, influences patient compliance and quality-of-life considerations. Finally, end users split between academic institutions and veterinary hospitals and clinics underscore the interplay between clinical practice environments and investigational research settings, each driving unique adoption curves for novel oncology solutions.

Dissecting Critical Regional Insights Across the Americas, Europe Middle East Africa, and Asia Pacific to Illuminate Geographical Variations in Veterinary Oncology Trends

Regional dynamics are pivotal to understanding how veterinary oncology takes shape across diverse markets. In the Americas, robust veterinary infrastructure, high pet ownership rates, and mature insurance frameworks have facilitated early adoption of advanced therapies and diagnostic modalities. The United States leads with a tightly regulated ecosystem that supports rapid commercialization, while Latin American markets are progressively investing in upgraded oncology capabilities, often through philanthropic and academic collaborations.

Europe, the Middle East, and Africa exhibit a heterogeneous landscape. Western European nations benefit from established veterinary oncology centers and comprehensive regulatory harmonization across the European Medicines Agency, accelerating product approvals. In contrast, Middle Eastern markets are rapidly building clinical capacity through public-private partnerships, and several African regions are initiating foundational oncology programs, frequently supported by international aid and capacity-building initiatives.

Meanwhile, Asia-Pacific is experiencing accelerated expansion propelled by rising disposable incomes, changing pet ownership patterns, and government incentives for biotech research. Japan and Australia feature sophisticated veterinary networks with integrated research consortia, whereas China and Southeast Asia are witnessing burgeoning private sector investment in oncology diagnostics and telehealth platforms. Collectively, these regional nuances underscore the necessity of tailored market entry strategies and local stakeholder engagement to harness growth in veterinary oncology.

Profiling Leading Industry Players and Strategic Company Insights Shaping the Competitive Landscape of the Veterinary Oncology Sector Through Innovation and Partnerships

An array of leading companies is shaping the competitive contours of veterinary oncology, characterized by strategic alliances and targeted R&D investments. Global pharmaceutical powerhouses have launched specialized animal health divisions focusing on oncology compounds, while mid-tier specialist firms are differentiating through proprietary biologics and vaccine platforms. Makers of diagnostic imaging equipment and software are forging partnerships with veterinary hospitals to embed AI-driven analysis tools within clinical workflows.

In parallel, emerging biotech startups are carving out niches by advancing novel immunotherapies and gene editing approaches tailored to companion animals. These ventures often collaborate with academic research centers to expedite translational pipelines and secure early-stage validation. Additionally, contract research organizations are expanding service offerings to include veterinary-specific toxicology and pharmacokinetic studies, thus underpinning streamlined development cycles.

Mergers and acquisitions remain active levers for growth, as larger entities seek to augment their oncology portfolios with innovative solutions and geographic reach. Simultaneously, joint ventures between industry and university laboratories are cultivating incubators that accelerate proof-of-concept trials. As a result, the market landscape is increasingly defined by cross-sector synergies, where shared expertise and resource pooling drive faster adoption of next-generation oncology modalities.

Delivering Actionable Recommendations for Industry Leaders to Navigate Market Complexity, Optimize Resource Allocation, and Harness Emerging Opportunities in Veterinary Oncology

Industry leaders must adopt a proactive stance to seize emerging opportunities and mitigate evolving risks within veterinary oncology. Prioritizing investments in immunotherapeutic research can unlock differentiated product pipelines, while scaling digital health solutions enhances diagnostic accuracy and client engagement. Furthermore, establishing partnerships with academic institutions accelerates access to translational research assets and bolsters credibility among clinical peers.

Simultaneously, stakeholders should explore decentralized manufacturing strategies to alleviate tariff-induced cost pressures and fortify supply chain resilience. Cultivating in-region production capabilities and forging alliances with contract manufacturers can reduce lead times and stabilize pricing, thereby preserving stakeholder margins. In parallel, implementing tiered pricing models and alternative financing structures can sustain treatment uptake in the face of rising patient expenses.

To maintain competitive advantage, organizations must foster multidisciplinary teams that bridge veterinary oncology, data science, and regulatory affairs. Embedding continuous learning frameworks and cross-functional collaboration will expedite innovation cycles and ensure compliance with evolving approval pathways. Lastly, devising region-specific go-to-market approaches-rooted in local stakeholder insights and regulatory landscapes-will optimize product launches and reinforce market penetration initiatives.

Outlining a Robust Research Methodology Incorporating Primary Interviews, Secondary Data Analysis, and Rigorous Triangulation to Ensure Reliable Veterinary Oncology Insights

This analysis is anchored in a rigorous research methodology that triangulates insights from primary and secondary data sources. Primary data collection involved in-depth interviews with veterinary oncologists, diagnostic laboratory directors, and academic researchers to capture first-hand perspectives on clinical efficacy, operational challenges, and unmet needs. Secondary research encompassed extensive review of peer-reviewed journals, clinical trial registries, patent filings, and regulatory filings to map technological advancements and approval trajectories.

Quantitative data points were refined through cross-validation techniques, ensuring consistency between independent sources and resolving discrepancies via follow-up inquiries. A comprehensive segmentation framework was constructed to parse market dynamics across animal types, treatment modes, cancer types, administration methods, and end-user categories. Regional market characteristics were analyzed in the context of regulatory environments, healthcare infrastructure maturity, and sociocultural pet ownership trends.

Where applicable, statistical modeling and scenario analysis were applied to assess the impacts of tariff changes and supply chain disruptions. Limitations include evolving trade policies and potential regulatory shifts scheduled beyond the research cutoff of Q1 2025. Overall, this methodology ensures that conclusions and recommendations are grounded in robust empirical evidence and reflect the most current state of veterinary oncology.

Drawing a Conclusive Synthesis of Key Findings, Strategic Implications, and Industry Narratives That Define the Current State and Future Trajectory of Veterinary Oncology

In summary, veterinary oncology is poised for sustained growth and innovation, fueled by technological breakthroughs, evolving treatment paradigms, and strategic industry collaborations. Key segmentation insights reveal nuanced opportunities across animal types and therapeutic modalities, while regional analyses underscore the importance of tailored approaches to market entry and expansion. The 2025 tariff realignment presents both challenges and incentives for nearshoring and supply chain optimization, demanding agile leadership and adaptive strategies.

Competitive dynamics are being reshaped by targeted R&D investments from biotechnology startups, strategic alliances between industry and academia, and consolidation moves among established animal health divisions. As decision-makers prioritize immunotherapy, precision diagnostics, and digital health integration, they should remain vigilant to regulatory developments and cost pressures that influence treatment accessibility.

By leveraging the actionable recommendations outlined herein-ranging from decentralized manufacturing to multidisciplinary team structures-industry stakeholders can navigate complexity and secure long-term value creation. This comprehensive synthesis of current trends and future trajectories equips enterprises to drive innovation, enhance patient outcomes, and achieve sustainable competitive advantage in the veterinary oncology landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Oncology Market, by Animal Type

  • 8.1. Canine
  • 8.2. Equine
  • 8.3. Exotic Pets
    • 8.3.1. Aquatic Pets
    • 8.3.2. Birds
    • 8.3.3. Reptiles & Amphibians
  • 8.4. Feline

9. Veterinary Oncology Market, by Treatment Mode

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Antimetabolites
    • 9.1.3. Cytotoxic Agents
    • 9.1.4. Vinca Alkaloids
  • 9.2. Immunotherapy
    • 9.2.1. Cancer Vaccines
    • 9.2.2. Monoclonal Antibodies
  • 9.3. Radiotherapy
    • 9.3.1. Brachytherapy
    • 9.3.2. External Beam Radiotherapy
  • 9.4. Surgery
  • 9.5. Targeted Therapy

10. Veterinary Oncology Market, by Cancer Type

  • 10.1. Hemangiosarcoma
  • 10.2. Lymphoma
  • 10.3. Mammary Carcinoma
  • 10.4. Mast Cell Tumors
  • 10.5. Osteosarcoma

11. Veterinary Oncology Market, by Mode of Administration

  • 11.1. Intravenous (IV)
  • 11.2. Oral
  • 11.3. Topical

12. Veterinary Oncology Market, by End User

  • 12.1. Academic Institutions
  • 12.2. Veterinary Hospitals & Clinics

13. Veterinary Oncology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Veterinary Oncology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Veterinary Oncology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Veterinary Oncology Market

17. China Veterinary Oncology Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AB Science SA
  • 18.6. Anivive Lifesciences
  • 18.7. Ardent Animal Health, LLC
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Ceva Sante Animale S.A.
  • 18.10. Covetrus, Inc.
  • 18.11. Elanco Animal Health Incorporated
  • 18.12. ELIAS Animal Health
  • 18.13. Fidocure
  • 18.14. IDEXX Laboratories, Inc.
  • 18.15. Karyopharm Therapeutics Inc.
  • 18.16. Leroy Biotech S.A.S.
  • 18.17. Merck KGaA,
  • 18.18. Morphogenesis, Inc.
  • 18.19. Nippon Zenyaku Kogyo Co., Ltd.
  • 18.20. PetCure Oncology LLC
  • 18.21. PharmAust Limited
  • 18.22. Rhizen Pharmaceuticals AG
  • 18.23. Torigen Pharmaceuticals Inc.
  • 18.24. Varian Medical Systems, Inc.
  • 18.25. Vetco Pharmaceuticals Inc.
  • 18.26. VetDC, Inc.
  • 18.27. Virbac SA
  • 18.28. VolitionRx Limited
  • 18.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VETERINARY ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY AQUATIC PETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY AQUATIC PETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY AQUATIC PETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BIRDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BIRDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BIRDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REPTILES & AMPHIBIANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REPTILES & AMPHIBIANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REPTILES & AMPHIBIANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY FELINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY FELINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY FELINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CYTOTOXIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CYTOTOXIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VINCA ALKALOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VINCA ALKALOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VINCA ALKALOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY HEMANGIOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY HEMANGIOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY HEMANGIOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAMMARY CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAMMARY CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAMMARY CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAST CELL TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAST CELL TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MAST CELL TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY OSTEOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY OSTEOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. NATO VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA VETERINARY ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY EXOTIC PETS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY TREATMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA VETERINARY ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)